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THE CLINICAL PROBLEM-SUDDEN CORONARY 
DEATH 
The management of ventricular rhythm disorders 
and the prevention of sudden coronary death con- 
tinue to be a major challenge for both the clinician 
and basic scientist. There is little doubt, from the 
very suddenness of and the ECG observations pre- 
ceding or accompanying sudden coronary death, 
that cardiac arrhythmias are the cause of this 
event-either ventricular asystole or ventricular 
fibrillation. In view of the incidence of sudden death 
in patients with coronary artery disease, effective 
therapeutic interventions would be desirable in 
those who are demonstrated to be at high risk. In 
addition, patients who have high risk of coronary 
artery and left ventricular characteristics for devel- 
oping a recurrent episode, need to be placed on 
prophylactic medical therapy. Thus survivors of 
myocardial infarction and that identifiable segment 
of the asymptomatic population with an ominous 
risk profile are demonstrably at very high risk of 
sudden death with at least two thirds of the deaths 
occurring in the first hour.’ There is ample evidence” 
attesting to the fact that sudden death is reversible. 
However, if an impact is to be made upon the high 
mortality due to sudden coronary death, it must 
depend upon the recognition and treatment of those 
at risk with the goal of preventing ventricular fibril- 
lation by a prophylactic therapeutic regimen. In 
reviewing the results of long-term suppressive ther- 
apy for the prevention of sudden coronary death, 
Lovell” stated that “nonspecific long-term use of 
existing drugs holds less promise than appeared at 
one time to be the case. It may be that tolerable 
drugs which are highly effective in inhibiting ven- 
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tricular fibrillation when given long-term will be 
developed, and this is a worthwhile aim.” 
AVAILABLE THERAPEUTIC INTERVENTIONS 
At present the antiarrhythmic drugs available in 
the United States for chronic management of 
patients with life-threatening arrhythmias are: 
quinidine, procainamide, disopyramide, proprano- 
101, timolol, and phenytoin. None is considered 
suitable for long-term prophylactic use in the pre- 
vention of sudden coronary death.” Of the new 
agents, aprindine, tocainide, mexiletine, encainide, 
ethmozin, flecainide, lorcainide, propafenone, pir- 
menol, verapamil, and diltiazem-none is known 
specifically to prevent ventricular fibrillation in 
either the experimental animal or in humans. In 
view of the long-term recognition of the primary role 
of ventricular fibrillation in sudden coronary death, 
it is most disappointing to note that the newer 
antiarrhythmic drugs were not developed specifical- 
ly for the problem under consideration, but are 
drugs that were in use in other countries or were 
discovered as part of a routine antiarrhythmic 
screen and were subjected subsequently to clinical 
studies. There are limited animal data with respect 
to these agents and already several are proving to 
have serious toxic effects.4 The approach to finding 
an effective antifibrillatory drug in contrast to an 
antiarrhythmic drug for the prevention of sudden 
coronary death has been one of mere chance alone 
and it is doubtful that this “hit-and-miss” method 
will ever prove successful. 
The almost “explosive” appearance of new class I 
antiarrhythmic agents which are effective in reduc- 
ing the frequency of premature ventricular depolar- 
izations but which lack specificity with respect to 
antifibrillatory activity, makes it unlikely that the 
current approach to identifying an agent capable of 
preventing sudden cardiac death will provide a 
solution to the problem at hand. The recent intro- 
duction of bretylium into clinical cardiology, howev- 
er, has suggested a new approach to the prevention 
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of life-threatening ventricular dysrhythmias. Al- - 
though the precise mechanism of its antifibrillatory 
action is not known, the effects of bretylium on the 
cellular electrophysiology of the heart have been 
studied and have been noted to differ from those of 
the class I antiarrhythmic drugs. 
Bretylium has been classified as belonging to a 
group of agents which are placed in class III because 
they have the property of increasing the action 
potential duration and prolonging the effective 
refractory period. Other members of this class 
include amiodarone, sotalol, pranolium, and clofil- 
ium. In the ischemic heart, bretylium decreases the 
disparity in action potential duration that exists 
between normal and ischemic regions.5 This action 
may account for the ability of bretylium to prevent 
the establishment of a reentry pathway and there- 
fore to protect against the initiation of ventricular 
fibrillation. 
The recent interest in bretylium as a potential 
agent for the suppression of recurrent ventricular 
tachyarrhythmias and recurrent ventricular fibrilla- 
tion is highlighted in the May and June, 1983, issues 
of THE JOURNAL, in which four groups of investiga- 
tors report on the electrophysiologic and antidys- 
rhythmic actions of the quaternary ammonium com- 
pound. Two of the papers report on the inability of 
bretylium to prevent the induction of sustained 
ventricular tachycardia by programmed electrical 
stimulation in patients known to be at risk of 
developing potentially lethal ventricular dysrhyth- 
mias. The first of these studies by Bauernfeind et 
al.‘j employed programmed electrical stimulation in 
a patient population known to have had sustained 
ventricular tachycardia and/or ventricular fibrilla- 
tion and who responded to programmed electrical 
stimulation with the induction of sustained ventric- 
ular tachycardia. All patients in this study were 
reported to have stable organic heart disease. The 
intravenous administration of bretylium was fol- 
lowed within 30 minutes by repeat testing with 
programmed electrical stimulation with 9 of the 10 
patients failing to show any degree of benefit. 
The second paper by Greene et a1.7 examines the 
efficacy of bretylium after 4 to 9 days of continuous 
intravenous drug infusions in five patients with 
recurrent, life-threatening ventricular arrhythmias 
and in whom the disturbances in cardiac rhythm 
were not related to acute ischemia. All patients had 
inducible ventricular tachycardia and/or ventricular 
fibrillation which was not prevented by bretylium 
given as a continuous infusion at the rate of 2.3 
mg/min for a minimum of 4 days and a maximum of 
9 days. It should be noted that in each of the studies 
cited, the patients had failed to exhibit beneficial 
effects from other antiarrhythmic drugs when 
assessed through the use of programmed electrical 
stimulation. In the latter report by Greene et a1.,7 a 
mean of 6.8 agents was used per patient before 
resorting to the use of intravenous bretylium. 
INDIRECT AND DIRECT CARDIAC ACTIONS OF 
BRETYLIUM 
In both animals and humans, the acute single dose 
administration of bretylium leads to a biphasic 
cardiovascular response. *-lo An initial release of nor- 
epinephrine from adrenergic nerve endings is 
accompanied by an acute rise in arterial pressure 
and heart rate. Within 20 to 30. minutes blood 
pressure, vascular resistance, and heart rate begin to 
decrease as peripheral sympathetic tone declines 
secondary to the adrenergic neuronal blocking 
effects of bretylium. These latter effects predomi- 
nate during the chronic phase of therapy and may be 
circumvented by the previous administration of a 
tricyclic antidepressant agent which would block the 
neuronal amine pump which transports bretylium 
into the adrenergic neurone, thereby preserving 
adrenergic sympathetic tone without altering the 
electrophysiologic and therapeutic effects of bretyl- 
ium upon the myocardium.lO,ll It is important to 
recognize that despite the presence of adrenergic 
neuronal blockade, intermittant and/or continuous 
administration of bretylium will lead to a repeated 
or sustained release of neuronal stores of norepi- 
nephrine. The acute administration of bretylium 
and the associated release of catecholamines is 
accompanied by a reduction in both the action 
potential duration5 and myocardial refractoriness12 
in normal ventricular myocardium. Furthermore, as 
a result of the associated catecholamine release from 
adrenergic nerve endings, the acute administration 
of bretylium often is accompanied by transient 
worsening of the cardiac rhythm.‘” The failure to 
achieve a satisfactory response during the initial 
early period of treatment with bretylium could be 
attributed to the fact that there is a delay in onset of 
action after the drug is administered by a continu- 
ous intravenous infusion and/or the associated 
release of catecholamines exerts an arrhythmogenic 
effect which predominates over the direct electro- 
physiologic actions of the quaternary ammonium 
compound. The existence of this latter mechanism is 
supported by the ability of propranolol (0.1 mg/kg) 
to enhance the ability of bretylium to prevent 
reentrant ventricular arrhythmias in the canine 
heart.13 
In a recent study by Anderson et a1.,14 bretylium 
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was administered as an initial dose of 5 mg/kg 
intravenously over a period of 15 minutes followed 
by a maintenance infusion of 1.5 mg/min for up to 90 
minutes. There was no significant change in intra- 
cardiac conduction, although there was a decrease in 
the cardiac muscle refractory period during the 75 to 
90 minutes of drug administration. These findings 
were to be expected after drug loading, as they are 
typical of changes associated with catecholamine 
stimulation of the heart. However, the continued 
refractory period shortening and facilitation of atria1 
and AV nodal conduction with no change in His- 
Purkinje and intraventricular conduction after 75 to 
90 minutes of drug therapy were unexpected initial- 
ly in view of earlier studies on isolated heart muscle 
and Purkinje fiber preparations,5. 15, l6 in which the 
effective refractory periods were prolonged-effects 
known to be independent of endogenous catechol- 
amine release. 
More recent studies with bretylium have con- 
firmed direct electrophysiologic actions during 
chronic therapy, but have noted adrenergic, not 
direct actions, during acute therapy.12s I79 l8 We deter- 
mined the kinetics of the antifibrillatory effects of 
bretylium and assessed the relative importance of 
myocardium us serum drug concentrations in 32 
dogs after they received rapid infusions of bretylium 
(6 mg/kg or 2 mg/kg) or saline so1ution.1E Parallel 
determinations were made of drug concentrations in 
serum and myocardium, together with antifibrillato- 
ry and cardiac electrophysiologic effects, both with 
and without 2 minutes of regional myocardial ische- 
mia produced by temporary coronary artery ligation. 
Serum bretylium concentration decreased rapidly 
after intravenous injection, whereas myocardial con- 
centrations increased gradually, peaking at 1.5 to 6 
hours. The ratio of myocardial to serum drug con- 
centration increased from 6.4 to 12.6 at 12 hours. 
Parallel eliminations of the drug in serum and 
myocardium occurred thereafter, with an elimina- 
tion half-life of 10.5 hours. Electrophysiologic and 
antifibrillatory effects paralleled myocardial rather 
than serum drug kinetics with peak effects at 3 to 6 
hours. The ventricular effective refractory period 
was 24 to 26 msec greater at 3 hours in dogs treated 
with the drug than in those receiving saline solution. 
The ventricular fibrillation threshold increased six- 
to tenfold within 3 to 6 hours in dogs receiving 2 
mg/kg of bretylium. The average increase in thresh- 
old exceeded twelvefold after administration of 6 
mg/kg of bretylium. The repetitive ventricular 
response threshold 3 hours after drug administra- 
tion increased fivefold after 2 mg/kg and eighteen- 
fold after 6 mg/kg in dogs with or without regional 
myocardial ischemia. 
These kinetic studies emphasize the importance 
of drug concentrations at tissue sites of action in the 
myocardium in determining therapeutic concentra- 
tions of the drug. Our data18 suggest that the kinetics 
of electrophysiologic and antifibrillatory effects of 
bretylium parallel those of drug accumulation in 
myocardial tissue. In contrast, the kinetics of cate- 
cholamine release and serum concentration of drug 
are dissimilar. Furthermore, dissociation of the 
antifibrillatory effects of bretylium from its ability 
to block adrenergic neurons is demonstrated by the 
observation that protriptyline, a tricyclic antide- 
pressant which prevents the accumulation of bretyl- 
ium in adrenergic nerves thus preserving neuronal 
function, does not interfere with the antiarrhythmic 
effects. These studies demonstrated marked time- 
and dose-dependent differences in response to bre- 
tylium. Clinical extrapolation of these data as in 
other animal studies must be tentative, but do 
suggest the need for repeated acute drug dosing and 
allowance of greater time after acute bretylium 
dosing before assuming drug failure.‘g-24 The delayed 
response in the increase in the ventricular fibrilla- 
tion threshold with small doses might be converted 
to an immediate response by a larger acute dose 
which results in a larger increase in the myocardial 
tissue concentration and electrophysiologic effects 
of the quaternary ammonium compound.lo~ l* The 
rapidity with which one can administer bretylium is 
limited, however, by its concomitant effects on the 
adrenergic neuronal stores of norepinephrine. 
The June, 1983, issue of THE JOURNAL contains a 
report by Fujimoto et a1.,25 who assessed the electro- 
physiologic effects of intravenous bretylium upon 
the conduction of premature impulses and excita- 
tion threshold in normal and ischemic myocardium. 
Bretylium was found to decrease the disparity in 
conduction times between the normal and the is- 
chemic myocardial tissue. These changes were asso- 
ciated with a delay in the conduction of impulses 
from normal myocardial tissue to the border of the 
ischemic heart muscle. In addition, bretylium also 
was noted to decrease the disparity between excita- 
tion thresholds of adjoining ischemic and normal 
myocardium. Of note was the observation that the 
significant effects of bretylium appeared to be late 
in onset (similar to the finding noted by our 
group13, I*), once again reflecting the time required to 
obtain a sufficient myocardial tissue concentration 
of drug to bring about a desired electrophysiologic 
effect. 
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THE ANTIARRHYTHMIC VERSUS ANTIFIBRILLATORY 
EFFECTS OF BRETYLIUM 
The two clinical reports6*7 presented in the May 
and June, 1983, issues of THE JOURNAL have failed to 
demonstrate the effectiveness of bretylium to pre- 
vent inducible ventricular tachyarrhythmia. Despite 
the fact that patients were given a continuous 
intravenous infusion of bretylium for 4 to 9 days,7 
the associated release of catecholamines would be 
occurring and could have negated any beneficial 
directly mediated electrophysiologic effects of the 
quaternary ammonium drug. Whereas catechol- 
amine release decays within 1 or 2 hours after a 
single dose, this is not the case with continuous or 
repeated bolus administration of bretylium.26 
The inability to document a beneficial action of 
bretylium in the prevention of inducible ventricular 
tachyarrhythmia as reported by Bauernfeind et al.6 
could, in effect, be attributed to the relative short 
duration between the administration of drug and 
the repeated efforts of programmed electrical stimu- 
lation. As discussed above, sufficient time may not 
have elapsed for myocardial tissue concentrations of 
the quaternary ammonium compound to have 
achieved an electrophysiologic effect. The inability 
of bretylium to prevent or suppress the induction of 
inducible tachyarrhythmia is not a unique observa- 
tion, since amiodarone, which is reported to be 
effective for long-term therapy of recurrent ventric- 
ular tachyarrhythmias, does not prevent arrhyth- 
mias in response to programmed electrical stimula- 
tion.27 These findings for both bretylium and amio- 
darone, two class III agents, contrast with other 
observations which favor the concept that a drug 
that fails to prevent ventricular tachycardia in 
response to programmed electrical stimulation will 
also fail to prevent the spontaneous development of 
ventricular tachyarrhythmia or, more importantly, 
ventricular fibrillation.28 Thus the question which 
arises is what end point does one select to provide 
proof of efficacy with respect to the ability of a given 
drug to protect against the development of a lethal 
dysrhythmia? There is a need to achieve a better 
understanding of the manner in which bretylium, 
and related class III drugs, should be administered 
to patients who are at high risk of developing 
life-threatening dysrhythmias. It is becoming more 
apparent that the early arrhythmias associated with 
acute myocardial ischemia, and most likely with 
sudden coronary death, are due to a reentry mecha- 
nism whereas the late occurring arrhythmias are 
most likely due to enhanced or abnormal automatic- 
ity.2g-32 It seems essential, therefore, in seeking a 
drug(s) that will prevent life-threatening dysrhyth- 
mias and sudden coronary death, that one conduct 
such studies in the early ischemic phase and record 
the associated electrical events. 
The use of an electrophysiologic protocol for drug 
selection is based on several assumptions: first, that 
the tachycardia produced in the laboratory by pro- 
grammed stimulation is identical to the clinical 
tachyarrhythmia; second, that the response to drug 
therapy in the laboratory predicts the clinical 
response; and third, that the ability to prevent the 
electrically induced ventricular tachycardia by drug 
treatment predicts the inability of the heart to 
develop ventricular fibrillation, especially if an is- 
chemic episode superimposes upon a vulnerable 
substrate. Is the prevention of electrically induced 
arrhythmias by drug therapy synonymous with the 
prevention of sudden coronary death? Thus whereas 
the first and second assumptions may be estab- 
lished, the latter is not, since an acute ischemic 
episode is not part of the testing procedure and the 
true efficacy of an intervention can only be deter- 
mined by looking at its potential to prevent sudden 
coronary death. Programmed electrical stimulation 
and acute pharmacologic testing may not be valu- 
able in helping to identify those at risk of sudden 
coronary death and in establishing treatment regi- 
mens. The identification of a truly effective agent 
will be determined by its ability to prevent ventric- 
ular fibrillation, an end point seldom achieved dur- 
ing provocative testing procedures. It may also be 
true that a drug that fails to prevent the initiation of 
tachyarrhythmia by programmed electrical stimula- 
tion may still successfully prevent a spontaneous 
recurrence. This would be especially true of those 
agents which accumulate in myocardial tissue over 
time and show little correlation between concentra- 
tion of drug in the plasma and therapeutic efficacy. 
Thus there is a need to reorient our thinking about 
the manner in which pharmacologic interventions 
may influence the final outcome in individuals at 
risk of sudden death due to disorders of ventricular 
rhythm. Since the lethal event is most often associ- 
ated with ventricular fibrillation, it may be s&Ii- 
cient to have an agent which prevents the develop- 
ment of this electrophysiologic disorder even though 
it does not show an ability to prevent or to suppress 
completely the electrical induction of tachyarrhyth- 
mias. 
A major problem in designing therapeutic 
approaches for the prevention of lethal ventricular 
dysrhythmias has been in the failure to use appro- 
priate animal models which permit evaluation of the 
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events occurring in the very first minutes of an 
ischemic episode superimposed upon a vulnerable 
substrate. The studies from our laboratory’s re- 
ported in the May, 1983, issue of THE JOURNAL, 
provide experimental data to show that bretylium 
has an ability to prevent the development of ventric- 
ular fibrillation in response to an acute ischemic 
event at a site remote from a previous myocardial 
infarction. In drug-treated animals programmed 
electrical stimulation performed 12 hours after the 
last bretylium dose was no longer effective in initi- 
ating a tachyarrhythmia, an event which coincided 
with observed changes in the electrophysiologic 
properties of the heart, characterized by the drug- 
induced prolongation in the effective refractory 
period. 
Thus bretylium has been classified as belonging to 
a group of agents which are placed in class III 
because they have the property of increasing the 
action potential duration and prolonging the effec- 
tive refractory period. In the ischemic heart, bretyl- 
ium decreases the disparity in action potential dura- 
tion that exists between normal and acutely ischem- 
ic regions. This action may account for the ability of 
bretylium to prevent the establishment of a reentry 
pathway and therefore protect against the initiation 
of ventricular fibrillation. 
Because of the potential role of quaternary ammo- 
nium derivatives as antifibrillatory drugs, our labo- 
ratory has examined a number of agents using the 
conscious canine model with chronic myocardial 
ischemia and programmed electrical stimulation for 
the induction of reentrant ventricular tachycardia. 
The recent description of a new quaternary ammo- 
nium compound, clofilium,33.21 with electrophysio- 
logic and antifibrillatory properties similar to those 
of bretylium, adds further support to the concept 
that drugs belonging to the members of class III may 
hold promise as specific antifibrillatory agents. The 
quaternary ammonium compounds, like bretylium 
and UM-272, are known to concentrate in normal 
and ischemic myocardium independent of their 
respective plasma concentrations.‘*,““-“$ Substantial 
amounts are absorbed from the gastrointestinal 
tract, contrary to the erroneous notion that intesti- 
nal absorption of monoquaternary amines does not 
occur~".36.37 
We have examined bretylium in a group of 
patients, each of whom has experienced one or more 
episodes of ventricular fibrillation. Initial therapy 
was instituted with intravenous bretylium and 
maintained with oral administration in dosages of 
300 to 400 mg every 8 hours. Repeated determina- 
tions of plasma and urinary concentrations of bre- 
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tylium have confirmed the fact that the drug is 
absorbed after oral administration.37 Although our 
series of patients is small, the fact that the patients 
remained free of life-threatening arrhythmias would 
suggest that bretylium as well as other quaterenary 
ammonium compounds deserve to be considered as 
potential antifibrillatory agents in the hope of 
reducing the incidence of sudden coronary death. If 
this proves to be the case, then there will be reason 
for optimism. 
The recent studies with aminodarone provide 
additional reason for hope that new therapeutic 
interventions which depart from the typical class I 
antiarrhythmic drugs may provide the proper elec- 
trophysiologic effects, so that the once vulnerable 
substrate presented by the ischemically injured 
myocardium becomes electrically more stable during 
the superimposition of a subsequent ischemic event, 
therefore preventing the induction of a reentrant 
rhythm and the development of a lethal arrhyth- 
mia.2” 
Substantial progress has undoubtedly been 
achieved in recent years with respect to identifying 
subsets of patients who are at risk of sudden coro- 
nary death. Both surgical and electrical means of 
preventing sudden death in the most difficult to 
manage patient groups have been attempted with 
impressive results. However, the national need con- 
tinues to demand that an increased priority be given 
to the development of more reliable and effective 
therapeutic agents capable of preventing ventricu- 
lar fibrillation. The challenge is formidable, but is 
one which can be met through the concerted efforts 
of basic and clinical investigators, respectively 
employing relevant animal models for the preclinical 
testing of potential therapeutic interventions and 
appropriate end points to determine clinical efficacy 
in a patient population known to be at an increased 
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